.png)
3D NAMs and models in Translational Research
AGENDA OVERVIEW
Webinar Agenda – 50 minutes
Topic: Advancing Translational Research with advanced 3D Non Animal Models (NAMs)
0–10 mins | Expert Interview: Davide Danovi
Davide Danovi, CSO, Migration Biotherapeutics, Visiting Senior Lecturer, King’s College London
A focused interview exploring the role of 3D NAMs including disease relevance, phenotyping, and applications in drug discovery.
10–50 mins | Panel Discussion: Advancing Translational Research with 3D Non Animal Models(NAMs)
- Introduction of cross sector research- clinical, academic & commercial
- Improving disease relevance with advanced 3D Non Animal Models(NAMs) & tradeoffs with content and throughput
- Regulatory Considerations
- Bridging preclinical insights to clinical translation for different cell types
Moderator: Davide Danovi, CSO, Migration Biotherapeutics, Senior Lecturer, King’s College London
Panellists:
- Peter Andersen, Chief Research & Development Officer, TreeFrog Therapeutics
- Timothy Lyden, Professor of Anatomy and Physiology , Director Tissue and Cellular Innovation Center, University of Wisconsin–River Falls
- Moin Saleem, Professor of Paediatric Renal Medicine; Founder and Chief Scientific Advisor, Purespring Therapeutics; University of Bristol and Bristol Royal Hospital for Children
Advancing CGT – Commercial & Regulatory Considerations
AGENDA OVERVIEW
Date Sept 14 , 2-2.50pm UK time
Advancing CGT – Commercial & Regulatory Considerations
Duration: 50 minutes
50 minutes mins | Panel Discussion: Advancing CGT – Commercial & Regulatory Considerations
- Balancing innovation, regulation and speed to market
- Building scalable manufacturing, quality and compliance strategies
- Commercialising advanced therapies in a challenging funding and access environment
Moderator: Konstantinos Gkatzis, Principal, UK & Europe, Epiceller
Panelists:
- Amir Hefni, CEO, Resolution Therapeutics
- Ruben Rizzi, Senior Vice President, Global Regulatory Affairs, BioNTech
- Christopher Middendorf, Senior Director, Technical, Pharma & Biotech GxP Compliance, Hogan Lovells
.jpg)
Biography:
Konstantinos is a biomedical scientist, venture capital fellow, bioethicist and founder of Epiceller, specializing in translational research, drug discovery, and healthcare investment. He has led multiple preclinical drug discovery programs and collaborates with global venture funds on biotech and digital health investments. He also serves as a scientific and ethic expert for non-profit organizations, supporting responsible and ethical innovation in medicine and emerging healthcare technologies.
Advances in Protein Expression and Production
AGENDA OVERVIEW
Tuesday, 6 October | 3:00–3:40 pm UK | 10:00-10:40 am EST
The session will explore key themes including:
- Current challenges in protein expression, purification, and quality control
- Why protein production remains a key bottleneck in drug discovery
- How improved data capture can support future machine learning models
- Lessons from difficult-to-express proteins and complex target classes
- How initiatives such as Target 2035 can help accelerate discovery
- Future opportunities for predictive models in protein production success
Confirmed panellists
- Kim Remans — Head of Protein Expression and Purification Core Facility, European Molecular Biology Laboratory
- Lovisa Holmberg Schiavone — Protein Sciences, Structure and Biophysics, Discovery Sciences, R&D, AstraZeneca
- Evgeny Tankhilevich — European Bioinformatics Institute, EMBL-EBI, Wellcome Genome Campus
Moderated by Nicola Burgess-Brown — Professorial Research Fellow in Protein Science, University College London; Chief Operating Officer, Protein Sciences, Structural Genomics Consortium
